Krystal Biotech, Inc. (KRYS)

NASDAQ: KRYS · IEX Real-Time Price · USD
59.04
2.11 (3.71%)
At close: May 20, 2022 4:00 PM
56.09
-2.95 (-5.00%)
After-hours:May 20, 2022 4:34 PM EDT
Market Cap1.51B
Revenue (ttm)n/a
Net Income (ttm)-103.72M
Shares Out25.64M
EPS (ttm)-4.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume145,171
Open58.23
Previous Close56.93
Day's Range55.69 - 60.12
52-Week Range38.86 - 102.99
Beta0.99
AnalystsBuy
Price Target112.46 (+90.5%)
Earnings DateMay 9, 2022

About KRYS

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other pre...

IndustryBiotechnology
IPO DateSep 20, 2017
Employees119
Stock ExchangeNASDAQ
Ticker SymbolKRYS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for KRYS stock is "Buy." The 12-month stock price forecast is 112.46, which is an increase of 90.48% from the latest price.

Price Target
$112.46
(90.48% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Der...

PITTSBURGH, May 19, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3 safety an...

1 day ago - GlobeNewsWire

Krystal Biotech, Inc. (KRYS) Reports Q1 Loss, Lags Revenue Estimates

Krystal Biotech, Inc. (KRYS) delivered earnings and revenue surprises of -3.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress

PITTSBURGH, May 09, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today reported financial results and key operational progress u...

1 week ago - GlobeNewsWire

Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference

PITTSBURGH, May 03, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Exec...

2 weeks ago - GlobeNewsWire

Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study

PITTSBURGH, April 11, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies, today announced that it plans to offer patients with dystrophic e...

1 month ago - GlobeNewsWire

Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC...

PITTSBURGH, March 28, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that results from the Phase 1...

1 month ago - GlobeNewsWire

New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting

PITTSBURGH, March 26, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc ., (“Krystal Biotech”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, presented more detailed results from ...

1 month ago - GlobeNewsWire

Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences

PITTSBURGH, March 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executi...

1 month ago - GlobeNewsWire

Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting

PITTSBURGH, March 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present late-brea...

2 months ago - GlobeNewsWire

Krystal Biotech Announces Settlement with PeriphaGen, Inc.

PITTSBURGH, March 15, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it has reached a binding term ...

2 months ago - GlobeNewsWire

Krystal Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Operational Progress

PITTSBURGH, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal” or the "Company") (NASDAQ: KRYS), the leader in redosable gene therapy, today reported financial results and key operation...

2 months ago - GlobeNewsWire

Krystal Biotech to Participate in Cowen's 42nd Annual Health Care Conference

PITTSBURGH, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive...

2 months ago - GlobeNewsWire

2 Biotech Stocks That Could Skyrocket This Year

For these two companies, the rewards could end up outweighing the risks.

Other symbols:EDIT
3 months ago - The Motley Fool

BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise

Krystal Biotech Inc (NASDAQ:KRYS) shares have potential to nearly double from current levels, according to an analyst at BofA Securities. The Krystal Biotech Analyst: Geoff Meacham initiated coverage of...

4 months ago - Benzinga

Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Boa...

PITTSBURGH, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing Marantz...

4 months ago - GlobeNewsWire

Could This Soaring Biotech Stock Make You Rich?

This company has made quite a lot of noise recently.

5 months ago - The Motley Fool

Why Krystal Biotech's Shares Rose More Than 77% This Week

The company had a positive phase 3 trial for its therapy to fight a rare genetic skin disease.

5 months ago - The Motley Fool

Why Krystal Biotech Stock Is Retreating Today

A public offering is weighing on the biotech's shares today.

5 months ago - The Motley Fool

Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock

PITTSBURGH, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previ...

5 months ago - GlobeNewsWire

Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock

PITTSBURGH, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $200...

5 months ago - GlobeNewsWire

Krystal Biotech shares are up 140% on Monday: here's the catalyst

Shares of Krystal Biotech Inc (NASDAQ: KRYS) more than doubled on Monday after the gene therapy company said its pivotal GEM-3 trial for VYJUVEK reported positive topline results. GEM-3 trial met its pr...

5 months ago - Invezz

KRYS Stock Alert: The Study Results That Have Krystal Biotech Rocketing 118% Today

Krystal Biotech (KRYS) stock is rising higher on Monday thanks to positive results from a recent Phase 3 clinical trial of VYJUVEK. The post KRYS Stock Alert: The Study Results That Have Krystal Biotech...

5 months ago - InvestorPlace

Krystal Biotech Shares More Than Double During Premarket Monday: What Investors Need To Know

Krystal Biotech Inc (NASDAQ: KRYS) has announced positive topline results from the GEM-3 Phase 3 trial of investigational beremagene geperpavec (B-VEC, Vyjuvek) for dystrophic Epidermolysis Bullosa (dys...

5 months ago - Benzinga

Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic E...

•  Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints, and its secondary endpoint of complete wound healing at three-month timepoints

5 months ago - GlobeNewsWire

Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress

–  Top-line results from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) on track for 4Q21

6 months ago - GlobeNewsWire